Octapharma Austria in the news

Octapharma expanded its public relations partnership with Brandenstein Communications to enhance its media visibility and promote the societal importance of plasma fractionation in Austria.

Octapharma significantly expanded its Vienna facility to boost plasma product production by 50% amid strong pharmaceutical sector growth in Austria.

A clinical trial showed Octapharma's 4F-PCC is superior to frozen plasma in reducing bleeding and complications during cardiac surgery.

Octapharma expanded its Vienna production site with new facilities and increased capacity to meet rising global demand for plasma products.

Octapharma expanded its production facility in Vienna with new 6,300 square meter areas, tripling its previous size, creating 160 new jobs, and significantly increasing production capacity to meet global demand for plasma products.

Octapharma inaugurated new production facilities in Vienna, expanding its capacity for plasma products to meet global demand and investing 200 million Euros.

Octapharma significantly expanded its Vienna plasma fractionation site, boosting capacity, jobs, and production to meet growing global demand for plasma products.

Octapharma Austria expanded its Vienna facility to increase blood plasma product manufacturing by 50% and plans further investments.

Octapharma invested 200 million euros to expand its Vienna facility, creating 160 jobs and boosting inspection, packaging, and logistics capacities.

Octapharma expanded its Vienna facility to boost plasma processing capacity and plans further investments amid rising global demand for plasma products.

Octapharma significantly expanded its Vienna facility to boost plasma product production by 50% amid growing global demand.

Octapharma invested 200 million euros to expand its Vienna site, adding 160 jobs and boosting production capacities.

Octapharma massively expanded its Vienna plasma fractionation site to boost production by 50% amid growing global demand and plans further investments and automation upgrades.

Octapharma operates a major plasma fractionation and production site in Vienna, expanding capacity and workforce while focusing on sustainability and employee benefits.

Octapharma will present new clinical and scientific data on treatments for rare bleeding disorders and acute bleeding management at the ISTH 2024 Congress.

Kelly Hearn has joined Octapharma USA as Vice President of Commercial Marketing and Development to lead product strategy and U.S. pipeline growth.

Octapharma's Vienna site is a major blood plasma product manufacturer investing in workforce growth, training, and employee benefits to support global patient care.

Octapharma's Vienna site is expanding its workforce development through a new international trainee program focused on blood plasma production and R&D.

Octapharma will present new clinical data on wilate® and Nuwiq® at EAHAD 2024, highlighting effective prophylaxis in von Willebrand disease and haemophilia A.

Octapharma USA introduced Balfaxar®, an FDA-approved prothrombin complex concentrate for urgent warfarin reversal in surgery, backed by strong clinical trial results and production capacity.